Mylan Inc.
4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
2
Ending by 2030
Jul 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Jan 7 to 9, 2027 · next Jan 7
- 2 fees due Mar 3 to 24, 2027 · next Mar 3
- 1 fee due May 3, 2027The maintenance fee for Medicament information system and method (US 9,179,260) comes due May 3, 2027. Unpaid by Nov 3, 2027, it lapses early.
- 1 fee due Aug 27, 2027The maintenance fee for Process for the continuous manufacture of a polyisobutylene based transdermal patch (US 11,911,522) comes due Aug 27, 2027. Unpaid by Feb 28, 2028, it lapses early.
- 1 fee due Sep 1, 2027The maintenance fee for Levothyroxine formulation with acacia (US 9,271,951) comes due Sep 1, 2027. Unpaid by Mar 1, 2028, it lapses early.
- 1 fee due Oct 28, 2027The maintenance fee for Process for the Continuous Manufacture of a Polyisobutylene Based Transdermal Patch (US 10,632,082) comes due Oct 28, 2027. Unpaid by Apr 28, 2028, it lapses early.
- 1 fee due Nov 10, 2027The maintenance fee for Controlled Release Levetiracetam Formulations and Methods for Producing the Same (US 9,333,175) comes due Nov 10, 2027. Unpaid by May 10, 2028, it lapses early.
Recent changes
- 1 term has ended since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,778,397 | Stabilized tolterodine tartrate formulations In force · From the USPTO record | In force | From the USPTO record | |
| US 10,632,082 | Process for the Continuous Manufacture of a Polyisobutylene Based Transdermal Patch In force · High confidence | In force | High confidence | |
| US 9,333,175 | Controlled Release Levetiracetam Formulations and Methods for Producing the Same In force · High confidence | In force | High confidence | |
| US 9,439,860 | Fenofibrate formulation In force · From the USPTO record | In force | From the USPTO record | |
| US 9,622,981 | Liquid-filled hard gel capsule pharmaceutical formulations In force · From the USPTO record | In force | From the USPTO record | |
| US 9,271,951 | Levothyroxine formulation with acacia In force · From the USPTO record | In force | From the USPTO record | |
| US 9,452,145 | Transdermal dosage form for low-melting point active agent In force · From the USPTO record | In force | From the USPTO record | |
| US 11,911,522 | Process for the continuous manufacture of a polyisobutylene based transdermal patch In force · From the USPTO record | In force | From the USPTO record | |
| US 9,179,260 | Medicament information system and method In force · From the USPTO record | In force | From the USPTO record | |
| US 9,736,642 | Medicament information system and method In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 26: 4 patents in force now held by others · 20 lapsed for an unpaid fee · 8 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 abandoned · 30 no status recorded